Baseline values of the 1223 patients with a known CCgR-status between 15 and 21 months
. | Total . | Learning sample . | Validation sample . |
---|---|---|---|
N | 1223 | 938 | 285 |
Male sex | 61% | 61% | 63% |
Median age, y (range) | 52 (18-83) | 52 (18-83) | 52 (18-77) |
Median spleen size* (range) | 1 (0-38) | 1 (0-38) | 0 (0-25) |
Baseline laboratory values | |||
Platelets (× 109/L), median (range) | 360 (34-3050) | 366 (34-3020) | 355 (113-3050) |
% Blast cells, median (range) | 1 (0-15) | 1 (0-15) | 1 (0-15) |
% Eosinophils, median (range) | 2 (0-20) | 2 (0-20) | 2 (0-14) |
Leukocytes, × 109/L, median (range) | 68 (1-571) | 63 (2-571) | 89 (2-520) |
Hb, g/dl, median (range) | 12 (2-18.2) | 12 (5-18) | 12 (6-18.2) |
% Basophils, median (range) | 3 (0-21) | 3 (0-21) | 4 (0-19) |
Treatment | |||
Imatinib 400 mg/d | 47% | 52% | 28% |
Imatinib 400 mg/d combined with LDAC or IFNα | 33% | 29% | 49% |
Imatinib 600 or 800 mg/d | 20% | 19% | 23% |
. | Total . | Learning sample . | Validation sample . |
---|---|---|---|
N | 1223 | 938 | 285 |
Male sex | 61% | 61% | 63% |
Median age, y (range) | 52 (18-83) | 52 (18-83) | 52 (18-77) |
Median spleen size* (range) | 1 (0-38) | 1 (0-38) | 0 (0-25) |
Baseline laboratory values | |||
Platelets (× 109/L), median (range) | 360 (34-3050) | 366 (34-3020) | 355 (113-3050) |
% Blast cells, median (range) | 1 (0-15) | 1 (0-15) | 1 (0-15) |
% Eosinophils, median (range) | 2 (0-20) | 2 (0-20) | 2 (0-14) |
Leukocytes, × 109/L, median (range) | 68 (1-571) | 63 (2-571) | 89 (2-520) |
Hb, g/dl, median (range) | 12 (2-18.2) | 12 (5-18) | 12 (6-18.2) |
% Basophils, median (range) | 3 (0-21) | 3 (0-21) | 4 (0-19) |
Treatment | |||
Imatinib 400 mg/d | 47% | 52% | 28% |
Imatinib 400 mg/d combined with LDAC or IFNα | 33% | 29% | 49% |
Imatinib 600 or 800 mg/d | 20% | 19% | 23% |
Learning sample comprised German, GIMEMA, and HOVON patients; validation sample comprised French and Nordic patients.12-16
Reported as cm below the costal margin as assessed by palpation.